483. Hereditary angioedema: pathophys, precipitants, Sx, Rx / Outpatient management of urticaria & angioedema / Clinical features and dx of mastocytosis

October 24th, 2008
by reuben in allergy

c1 esterase deficiency

Back Top

Responses to “483. Hereditary angioedema: pathophys, precipitants, Sx, Rx / Outpatient management of urticaria & angioedema / Clinical features and dx of mastocytosis”

  1. Please also know that while FFP has replacement C1 INH, it also has bradykinin and kalikrein which are known mediators for the swelling attack. FFP works wonderfully for some patients, but not for all. For some, because of the Kalikrein & Bradykinin, FFP could possibly exacerbate the swelling attack or lead to a rebound attack that was worse than the initial attack. C1 Inhibitory gained FDA approval on October 10th and is the preferred treatment option for HAE. Please see http://www.haea.org for up to date treatment options as well as pathophysiology and diagnosis recomendations from some of the world’s leading experts in HAE.

    shelby7185 at

Leave a Reply